These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 20110783)
1. Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma. Puente J; Manzano A; Martin M; López-Tarruella S; Díaz-Rubio E Anticancer Drugs; 2010 Jan; 21 Suppl 1():S19-22. PubMed ID: 20110783 [TBL] [Abstract][Full Text] [Related]
2. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment]. Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029 [TBL] [Abstract][Full Text] [Related]
3. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566 [TBL] [Abstract][Full Text] [Related]
4. [Metastatic breast cancer treated with trastuzumab and paclitaxel--a case report with clinically complete response]. Yoshida T; Horiguchi J; Koibuchi Y; Kanoh T; Iijima K; Yoshida M; Kikuchi M; Takata D; Oyama T; Iino Y; Morishita Y Gan To Kagaku Ryoho; 2004 Jun; 31(6):907-10. PubMed ID: 15222110 [TBL] [Abstract][Full Text] [Related]
5. [Two cases treated with trastuzumab as primary chemotherapy]. Murakami K; Sakata H; Miyazawa Y; Matsushita K; Akutsu Y; Nishimori T; Yoneyama Y; Usui A; Kano M; Matsubara H; Ochiai T Gan To Kagaku Ryoho; 2007 Oct; 34(10):1683-7. PubMed ID: 17940391 [TBL] [Abstract][Full Text] [Related]
6. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Robert NJ; Saleh MN; Paul D; Generali D; Gressot L; Copur MS; Brufsky AM; Minton SE; Giguere JK; Smith JW; Richards PD; Gernhardt D; Huang X; Liau KF; Kern KA; Davis J Clin Breast Cancer; 2011 Apr; 11(2):82-92. PubMed ID: 21569994 [TBL] [Abstract][Full Text] [Related]
7. Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer. Shimizu T; Hirano A; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Kim N; Ogawa K; Fujibayashi M Anticancer Res; 2010 Feb; 30(2):581-5. PubMed ID: 20332474 [TBL] [Abstract][Full Text] [Related]
8. A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment. Shigematsu H; Nakamura Y; Tanaka K; Shiotani S; Koga C; Kawaguchi H; Nishimura S; Taguchi K; Nishiyama K; Ohno S Int J Clin Oncol; 2010 Dec; 15(6):615-20. PubMed ID: 20473628 [TBL] [Abstract][Full Text] [Related]
9. [Preoperative therapy with trastuzumab and paclitaxel in a stage IV advanced breast cancer with complete pathologic response]. Rai Y; Sagara Y; Sagara Y; Takahama T; Matsuyama Y; Ando M; Sagara Y; Ooi Y; Inoue K; Kurosumi M Gan To Kagaku Ryoho; 2007 Jan; 34(1):65-8. PubMed ID: 17220672 [TBL] [Abstract][Full Text] [Related]
10. [Two cases of breast cancer responding to primary systemic chemotherapy containing trastuzumab without surgery]. Konishi K; Hasegawa N; Kaneko H; Iimura Y; Shoji Y; Kawabata M Gan To Kagaku Ryoho; 2010 Jan; 37(1):115-8. PubMed ID: 20087043 [TBL] [Abstract][Full Text] [Related]
11. Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery. Nomura M; Inoue Y; Fujita S; Sakao J; Hirota M; Souda S; Ohshima M Breast Cancer; 2005; 12(3):226-30. PubMed ID: 16110294 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. Leyland-Jones B; Gelmon K; Ayoub JP; Arnold A; Verma S; Dias R; Ghahramani P J Clin Oncol; 2003 Nov; 21(21):3965-71. PubMed ID: 14507946 [TBL] [Abstract][Full Text] [Related]
13. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640 [TBL] [Abstract][Full Text] [Related]
14. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer]. Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072 [TBL] [Abstract][Full Text] [Related]
15. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium. Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555 [TBL] [Abstract][Full Text] [Related]
16. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Mayer EL; Dhakil S; Patel T; Sundaram S; Fabian C; Kozloff M; Qamar R; Volterra F; Parmar H; Samant M; Burstein HJ Ann Oncol; 2010 Dec; 21(12):2370-2376. PubMed ID: 20497961 [TBL] [Abstract][Full Text] [Related]
17. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study. Janku F; Pribylova O; Zimovjanova M; Pazdrova G; Safanda M; Zemanova M; Petruzelka L Bull Cancer; 2004 Oct; 91(10):E279-83. PubMed ID: 15582895 [TBL] [Abstract][Full Text] [Related]
18. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity. Nisticò C; Bria E; Vaccaro V; Cuppone F; Fornier M; Sperduti I; Carpino A; Izzo F; Tropea F; Cognetti F; Terzoli E Anticancer Drugs; 2009 Feb; 20(2):109-14. PubMed ID: 19209027 [TBL] [Abstract][Full Text] [Related]
19. Prolonged trastuzumab therapy in a patient with recurrent breast cancer and anthracycline-induced cardiac failure. Walji N; Bhatt L; Dhallu S; Fernando IN Breast; 2008 Aug; 17(4):423-5. PubMed ID: 18479923 [TBL] [Abstract][Full Text] [Related]
20. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]